Mechanistic Insights and Therapeutic Potentials of Ubiquitin-Proteasome System in Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Non-small cell lung cancer (NSCLC) presents significant mortality challenges due to tumor heterogeneity, limiting current targeted therapies and immunotherapies.
• The ubiquitin-proteasome system (UPS), a critical regulator of protein stability, is implicated in cancer pathogenesis, influencing oncogenic pathways and tumor progression.
• Understanding the UPS's role is vital for developing novel therapeutic strategies against NSCLC.

Approach:

• This review systematically examines the UPS as a therapeutic target for NSCLC.
• It highlights recent preclinical and clinical research on ubiquitination-related biomarkers and drug targets.
• Emerging therapies, including proteasome inhibitors and Proteolysis-targeting chimeras (PROTACs), are discussed.

Key Points:

• Ubiquitination, a key post-translational modification, significantly impacts NSCLC biology, progression, and therapeutic response.
• The UPS influences oncogenic pathways and tumor development, making it a promising target.
• Biomarkers and novel therapeutic agents targeting the UPS are under active investigation.

Conclusions:

• Targeting the ubiquitination-deubiquitination system presents a promising complementary or synergistic approach to existing NSCLC treatments.
• Exploiting the UPS can potentially enhance patient outcomes and overcome therapeutic resistance in NSCLC.
• Further research into UPS-targeted therapies is crucial for advancing NSCLC treatment paradigms.